Company ProfilePremium

Alchemist Limited

Company Profile Analysis

Tickers: ALCHEM.NS, 526707.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alchemist Limited - Company showcase

Year Founded & Workforce

1988

189 Employees

Alchemist Limited logo

Alchemist Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alchemist Limited Overview

FieldDetailSource
Legal nameAlchemist LimitedBSE / IBBI records
Corporate Identification Number (CIN)L72200DL1988PLC192643IBBI public announcement
Former namesToubro Industries Ltd → Toubro Infotech & Industries Ltd (renamed 2000) → Alchemist Limited (w.e.f. 29 Dec 2004). Note: CRISIL describes the original name as "Toubro Infotech & Industries Ltd"; Wikipedia describes the group's predecessor as "Turbo Industries." Discrepancy flagged.IIFL company summary; CRISIL rationale Nov 2025; Wikipedia (K.D. Singh)
Founding / incorporationIncorporated 5 July 1988 (CIN and BFSL data). IIFL states 1981; CRISIL states 1988. The 1988 date is consistent with the CIN and is treated as authoritative.BFSL/Vogue data; CRISIL; IIFL
FounderDr Kanwar Deep Singh ("K.D. Singh"), former Rajya Sabha MPCRISIL; Wikipedia
Incorporation jurisdictionNational Capital Territory of Delhi, India (Companies Act)CIN prefix "DL"
Headquarters / registered officeAlchemist House, Building No. 23, Nehru Place, New Delhi 110019, India. Tel +91 11 4060 0800Yahoo Finance profile; BFSL
Stock exchanges and tickersNSE: ALCHEM (series BZ); BSE: 526707. MCX-SX also listed historically.Screener.in; BFSL
ISININE964B01033NSE press release 27 Jul 2007; Business Standard
CUSIPNot applicable (no US listing)—
Face value₹10 per share (consolidated from ₹1 to ₹10 effective 31 Jul 2007)NSE press release 27 Jul 2007
Shares outstanding (derived)Approximately 1.36 crore (13.6 million) shares, derived from equity capital of ~₹14 Cr at ₹10 face value and from FY2020 EPS of -₹34.46 on a net loss of ₹47 CrDerived from Screener.in
Fiscal year end31 MarchAnnual reports
Registrar & transfer agentMUFG Intime India Pvt Ltd (formerly Link Intime), New DelhiBFSL
Employees (latest)189 full-time (date of data point not specified by aggregator; likely FY2020)Yahoo Finance; MarketScreener
Employee 3-year trendNot publicly disclosed in sources reviewed. Insolvency claims list (Jul 2022) shows 60 employee claims totalling ₹3.70 Cr, indicating unpaid staff dues.IBBI list of creditors 29 Jul 2022
Auditor——
Market capitalisation₹4.08 Cr at last traded price of ₹3.01 (13 Dec 2021); free-float market cap ₹2.66 Cr. No live market price exists.BSE quote page; Screener.in
Book value per share-₹283 (negative; Sep 2020 balance sheet)Screener.in
Credit ratingCRISIL D (Issuer Not Cooperating), reaffirmed 27 Nov 2025, on ₹32.5 Cr bank facilitiesCRISIL rationale
Insolvency statusCIRP admitted 30 Nov 2021 (IB-275/ND/2020); recalled by NCLT New Delhi Bench IV on 3 Feb 2026; moratorium lifted; RP appointment nullifiedIBBI order register; Moneylife; LiveLaw
Listing statusTrading suspended; BSE quote page flags suspension due to non-payment of annual listing fee (ALF) duesBSE
Websitehttp://www.alchemist.co.inCompany
Investor emailinvestors@alchemist.co.inBFSL

The entity profiled is the listed company identified by the user's details. Name, ticker and website are unchanged; the listing has not moved, but trading is suspended.

Alchemist Limited is the original listed flagship of the Delhi-headquartered Alchemist Group founded by K.D. Singh. Once a diversified mid-cap trading and agri-processing company with peak standalone revenue of ₹827 Cr (FY2014), it described itself in its final reporting years as engaged in agriculture and allied activities (floriculture), manufacture of welded wire mesh for the poultry industry, and trading of chemicals and pharmaceutical formulations, operating plants at Solan and Sirmour (Himachal Pradesh) and Ropar (Punjab). Since FY2015 the company has been economically inert: revenue collapsed to ₹14 Cr by FY2020, net worth turned deeply negative, borrowings of roughly ₹764–767 Cr remain unserviced, and ~₹475 Cr of receivables appear to have been written down in Q2 FY2021. Today the company's value proposition is entirely legal and forensic: its fate turns on PMLA attachment, investor-restitution litigation in the Calcutta High Court, and the aftermath of a CIRP the NCLT found fraudulent.


Company's own description

In its last annual reports and as reflected in exchange and data-vendor profiles derived from them, Alchemist Limited describes itself as being "engaged in the business of agriculture and allied activities comprising of floriculture and manufacturing of wire mesh for poultry industry and trading of chemicals and pharmaceutical formulations" (Screener.in company summary, sourced from FY2020 annual report). Data vendors drawing on the same filings state that the company reports two segments — Agri Business and Pharma, Chemical & Minerals — with a pharma unit at Solan (Himachal Pradesh), a steel/wire unit at Ropar (Punjab), a floriculture unit at Sirmour (Himachal Pradesh), and a subsidiary named Alchemist Healthcare Limited (MarketScreener profile).

Older company descriptions (IIFL summary) present a much broader conglomerate scope — steel, floriculture, pharma, hospitality, real estate, information technology, food processing, healthcare and international business — reflecting the pre-2015 era when the listed company sat at the centre of group activity. CRISIL's 2025 rationale describes the company as a diversified corporation with operations in chemical trading, pharmaceuticals, food-processing, floriculture, and steel.

Independent characterisation

The financial record supports a sharper characterisation. Between FY2009 and FY2014, revenue grew from ₹386 Cr to ₹827 Cr while operating margins compressed from 8% to 1.5% — the profile of a low-margin trading business (chemicals, minerals and similar commodities) layered on top of small manufacturing assets. In FY2014, borrowings jumped from ₹302 Cr to ₹773 Cr and "other assets" (predominantly receivables) from ₹153 Cr to ₹714 Cr, with operating cash flow of -₹255 Cr funded by +₹431 Cr of financing inflows. Revenue then fell to ₹252 Cr in FY2015 and ₹19 Cr in FY2016, while debtor days exploded from 168 (FY2014) to 9,151 (FY2016). In plain terms, the company borrowed heavily, booked trading sales on credit, and those receivables were never collected.

From FY2016 to FY2020 the residual operating business — wire mesh, floriculture and pharmaceutical formulation trading — generated ₹14–27 Cr of annual revenue at deeply negative operating margins (-36% to -354%). The September 2020 quarter recorded expenses of ₹373 Cr against revenue of ~₹1 Cr, most plausibly a write-off of the legacy receivables, partly offset by ₹124 Cr of other income (most plausibly a write-back of liabilities; "other liabilities" fell from ₹161 Cr to ₹42 Cr in the same period). The company is best characterised today as a legacy shell holding impaired assets, ~₹764 Cr of debt, and contested claims, embedded in a group under criminal investigation.

Business and revenue model

DimensionCharacterisation (last reported period, FY2020 / H1 FY2021)
Revenue modelProduct sales (wire mesh, flowers) and traded goods (pharma formulations, chemicals). No subscription, licensing or service revenue disclosed.
Product vs. service mixEffectively 100% product/trading; split not publicly disclosed in sources reviewed
Value-chain positionSmall-scale downstream manufacturer (wire drawing/mesh welding; cut-flower cultivation) and distributor/trader (pharma formulations, chemicals)
Customer typesPoultry farms and fencing buyers (wire mesh); flower wholesalers; pharmacies/distributors (formulations); industrial buyers (chemicals)
End-marketsIndian poultry and construction/fencing; domestic floriculture; domestic pharmaceutical retail
ScaleFY2020 revenue ₹14 Cr; TTM to Sep 2020 ₹6 Cr
Current operating statusNot publicly disclosed; no filings after Q2 FY2021. CIRP-era disclosures and the RP's management of assets (Dec 2021–Feb 2026) suggest minimal or no operations.

Strategy

The company has published no strategy statement, investor presentation, investor day, medium-term targets or guidance since at least FY2020. The FY2020 annual report's description focuses on maintaining the agri (floriculture, wire mesh) and pharma/chemical trading activities; no transformation programme, ESG commitment or cost-reduction target is publicly disclosed.

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026): none announced by the company. The only "strategic" developments are legal:

Management medium-term financial targets: not publicly disclosed.

Products & Services

Agri Business

Product lineDescription and capabilitiesTarget customerLaunch / latest yearPricing modelSource
Welded wire mesh ("Alchemist Steel")Welded wire mesh manufactured in 100 grades at Ropar, PunjabPoultry farms (cages, enclosures), constructionOperational through FY2020; launch year not disclosed—IIFL; MarketScreener
Steel wires for barbed and razor wireWire used by fabricators to make barbed and razor wireFencing fabricators——Yahoo Finance profile
Chain-link and other wire fencingFencing products for poultry and for residential/non-residential buildingsPoultry, real estate, institutional buyers——Yahoo Finance profile
FloricultureCut-flower cultivation at Sirmour, HP; a solar energy device was developed for the floriculture unit in FY1995Flower wholesalers, domestic/export marketsUnit dates to the 1990s—IIFL; MarketScreener

Pharma, Chemical & Minerals

Brand / lineDescription / indicationTarget customerYearPricingSource
Anemi-XTFormulation for iron deficiencyPrescribers, pharmacies——FMP / MarketScreener
Valcal-MFormulation for calcium deficiencyPrescribers, pharmacies——FMP / MarketScreener
IGTG ForteFormulation marketed for weak immunityPrescribers, pharmacies——FMP / MarketScreener
GaseaseGastrointestinal formulationPrescribers, pharmacies——MarketScreener
Wider therapy portfolioImmune enhancers, nutraceuticals, antibacterials, gastrointestinals, pain relievers, anti-allergics, anti-cold, steroids, enzymes, supplements, CNSDomestic pharma retail——FMP / MarketScreener
Chemicals and minerals tradingTrading of chemicals and minerals; historically the bulk of revenue (inferred from FY2009–FY2014 margin profile)Industrial buyers——Screener.in; CRISIL

Discontinued / historical lines

LineDescriptionPeriodSource
Chicken processingPlant with 4,000 birds/hour capacityCommissioned FY2000IIFL
Republic of Chicken (retail)Branded retail stores in DelhiFrom FY2008IIFL
Republic of Chicken (restaurants)National restaurant chain build-out (via Alchemist Foods)From FY2009IIFL
Hospitality, real estate, IT, healthcareListed in older company summaries as business areasPre-2015IIFL

Financial Narrative

Basis: Standalone, ₹ Cr, as compiled by Screener.in from audited annual reports FY2016–FY2020 (BSE). Figures are rounded to the nearest crore by the source; ratios computed from rounded figures carry rounding error. No audited financials have been published for FY2021 or later; H1 FY2021 (to 30 Sep 2020) is shown separately.

Income statement

Gross profit and diluted EPS are not separately disclosed in the compiled data; there are no dilutive instruments disclosed, so diluted EPS is presumed equal to basic.

Margins and growth

Revenue CAGR FY2016–FY2020: -7.4% (₹19 Cr to ₹14 Cr). Screener.in reports 5-year compounded sales growth of -44%, 10-year of -28% and 3-year of -15% (measured to TTM Sep 2020).

Interim: H1 FY2021 (last published results)

TTM to Sep 2020: revenue ₹6 Cr; net loss ₹228 Cr; EPS -₹168.41. Business Standard reports a consolidated Q2 FY2021 loss of ₹185.62 Cr on total income of ₹124.86 Cr, consistent with the standalone data.

Balance sheet

Sep 2020 half-year balance sheet: reserves -₹397 Cr; borrowings ₹764 Cr; other liabilities ₹42 Cr; total assets ₹422 Cr; other assets ₹116 Cr.

Not publicly disclosed in compiled data: cash and equivalents separately; short-term vs long-term debt split; goodwill and intangibles; working capital. Insolvency claims provide a cross-check on debt: financial creditor claims admitted totalled ₹914.92 Cr (19 Jan 2022, then classed as secured, 3 claims) and ₹919.49 Cr (29 Jul 2022, reclassified as unsecured, 5 claims) — higher than book borrowings, likely reflecting accrued interest. This classification shift between lists is itself a discrepancy worth noting.

Cash flow

Capex is not separately disclosed in compiled data; the gap between CFO and FCF implies negligible net capex (FY2017 and FY2018 FCF exceed CFO, implying small net asset-disposal inflows of ~₹5 Cr and ~₹1 Cr).

Ratios

NM = not meaningful (negative equity or negative EBITDA). Net debt/EBITDA is not meaningful in every year (negative EBITDA). Current ratio and ROIC are not publicly disclosed in compiled data; ROCE is the closest proxy. Screener.in flags contingent liabilities of ₹315 Cr.

Commentary

Revenue. The defining inflection is FY2015: revenue fell 70% to ₹252 Cr, then 92% to ₹19 Cr in FY2016. The FY2009–FY2014 revenue growth (CAGR ~16%) came with continuously declining margins, a pattern consistent with volume-driven commodity trading rather than value-added manufacturing. Once trading stopped — coinciding with the period in which SEBI and later the ED began scrutinising the group's fund flows — the residual business was tiny.

Profitability. Every year since FY2015 has been loss-making. FY2017's ₹107 Cr loss was driven by negative other income of ₹69 Cr; investments fell by ₹73 Cr that year (₹244 Cr to ₹171 Cr), indicating an impairment of investments booked through other income. FY2019 and FY2020 losses of ₹50 Cr and ₹47 Cr were driven by expenses far exceeding revenue (₹80 Cr and ₹65 Cr), likely including provisions against receivables.

Balance sheet. Net worth went from ₹25 Cr (FY2016) to -₹196 Cr (FY2020) and -₹383 Cr (Sep 2020; equity ₹14 Cr plus reserves -₹397 Cr). Borrowings have been essentially static at ₹727–767 Cr for six years, meaning interest is either not being accrued in the P&L at contractual rates (interest expense of just ₹1–3 Cr on ~₹750 Cr of debt implies an effective rate below 0.5%) or debts are owed to parties not charging interest. This is a major red flag: either the debt is owed largely to related parties, or interest is not being recognised. The NCLT's 2026 finding that the Committee of Creditors was dominated by "related and interested entities" accused of criminal misconduct supports the former reading.

Receivables. Implied receivables of roughly ₹430–480 Cr sat on the balance sheet from FY2016 to FY2019 against annual revenue of ₹19–27 Cr. The Sep 2020 quarter's ₹373 Cr expense line and the ₹308 Cr fall in "other assets" (₹424 Cr to ₹116 Cr) are consistent with a large write-off of these receivables.

Cash flow. FY2016's +₹114 Cr operating cash flow, matched by -₹139 Cr investing outflow (investments rose ₹140 Cr), suggests collections were redeployed into investments (possibly group entities) rather than used to repay debt. From FY2017, operations consumed cash every year, funded by small financing inflows (₹5–16 Cr).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/servicesFacilities

Agri Business

Floriculture; welded wire mesh and wire products for the poultry industry (vendors classify the steel unit under agri given its poultry end-market)

Cut flowers; welded wire mesh (100 grades), barbed/razor wire inputs, chain-link fencing

Floriculture: Sirmour, HP; Steel/wire: Ropar, Punjab

Pharma, Chemical & Minerals

Trading and marketing of pharmaceutical formulations; chemical and mineral trading

Branded formulations (Anemi-XT, Valcal-M, Gasease, IGTG Forte and others); traded chemicals/minerals

Pharma unit: Solan, HP

Segment revenue (INR Cr, standalone)

Segment revenue (INR Cr, standalone)FY2018FY2019FY2020

Total revenue (INR Cr)

272714

Total revenue YoY growth (%)

130-48

Results by Segment

Segment results (INR Cr)FY2018FY2019FY2020

Total operating profit before other income (INR Cr)

-10-53-51

Group Entities

EntityRelationshipStatusSource

Alchemist Healthcare Limited

Subsidiary (per latest vendor profile)

—

MarketScreener

Alchemist Foods Ltd

Wholly owned subsidiary acquired Feb 2009 (Republic of Chicken)

Current status not publicly disclosed

IIFL

Alchemist Infra Realty Ltd

Group company (not a disclosed subsidiary) — subject of SEBI CIS order and ED attachment

Under PMLA proceedings

ED via media

Alchemist Township India Ltd

Group company — CIRP from 25 Jan 2019; stayed by NCLT 10 Jun 2026 per Calcutta HC direction

Under CIRP (stayed)

IBBI; ATIL RP site

Alchemist Holdings Ltd

Group company — CIRP admitted 4 Jun 2025 on petition of KDS Corporation Pvt Ltd

Under CIRP

IBBI

Alchemist Capital Ltd

Group company — CIRP admitted 1 Aug 2025 (NCLT Chandigarh)

Under CIRP

IBBI

Alchemist Corporation Ltd (BSE 531409)

Separately listed, formerly Haryana Fibres Ltd; group affiliation historically

Listed, trading

Screener.in; Pocketful

Alchemist Hospitals / Ojas Hospital (Panchkula)

Group-linked hospitals; ₹127.33 Cr of shares held by Sorus Agritech attached by ED

Attached under PMLA

Moneylife

“—” = not publicly disclosed.

Income Statement and Per-Share Data

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (INR Cr)

1924272714

Total expenses (INR Cr)

4553368065

EBITDA / operating profit (INR Cr)

-26-29-10-53-51

Other income (INR Cr)

19-69310

Depreciation (INR Cr)

98877

Interest (INR Cr)

32211

EBIT derived as PBT plus interest (INR Cr)

-16-106-14-60-57

Pre-tax income (INR Cr)

-19-108-16-61-58

Net income (INR Cr)

-21-107-17-50-47

EPS basic (INR)

-15.40-79.06-12.47-36.61-34.46

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2016FY2017FY2018FY2019FY2020

EBITDA margin (%)

-136-122-36-199-354

EBIT margin derived (%)

-84-442-52-222-407

Net margin derived (%)

-111-446-63-185-336

Revenue YoY growth (%)

-9226130-48

Income Statement and Margin Analysis (%)

MetricFY2009FY2010FY2011FY2012FY2013FY2014FY2015

Revenue (INR Cr)

386396411522667827252

EBITDA (INR Cr)

323215131612-32

EBITDA margin (%)

883.52.62.41.5-13

Net income (INR Cr)

14168161617-20

EPS (INR)

11.5012.916.6312.5111.9512.29-14.72

Borrowings (INR Cr)

151157185316302773704

Debtor days

161615124168659

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data (Quarterly)

Metric (INR Cr, standalone)Q1 FY2021 (Jun 2020)Q2 FY2021 (Sep 2020)

Revenue

11

Expenses

1373

Other income

0124

Pre-tax income

-1-250

Net income

-2-186

EPS (INR)

-1.15-136.85

Balance Sheet and Working Capital (Days)

Metric (INR Cr, standalone, 31 Mar)FY2016FY2017FY2018FY2019FY2020

Equity share capital

1414141414

Reserves

11-96-113-163-210

Total equity (net worth)

25-82-99-149-196

Borrowings (total debt)

727740752763767

Other liabilities

173178170161161

Total liabilities and equity

925835822774733

Fixed assets (net)

174162154147140

Capital work in progress

20000

Investments

244171169169169

Other assets (incl. receivables, inventory, cash)

505503500459424

Implied trade receivables derived from debtor days

476476479430368

Cash Flow

Metric (INR Cr)FY2016FY2017FY2018FY2019FY2020

Operating cash flow

114-24-14-7-4

Investing cash flow

-13994-30

Financing cash flow

22161095

Net cash flow

-310-10

Free cash flow (per Screener)

114-19-13-7-4

Dividends paid

00000

Buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2016FY2017FY2018FY2019FY2020

ROE on closing equity (%)

-84————

ROA on closing assets (%)

-2.3-12.8-2.1-6.5-6.4

ROCE per Screener (%)

-2-5-2-9-10

Debt to equity (x)

29.1————

Interest coverage EBIT over interest (x)

-5.3-53.0-7.0-60.0-57.0

Asset turnover (x)

0.020.030.030.030.02

Debtor days

9,1517,2326,4715,8079,597

Inventory days

196114361920

Payable days

4,0262,6412,5542,4304,894

Cash conversion cycle (days)

5,3214,7063,9523,3974,724

Geographic revenue (INR Cr)

Geographic revenue (INR Cr)FY2018FY2019FY2020

Total revenue (INR Cr)

272714

Valuation Snapshot

MetricValueSource

Last traded price

₹3.01 (13 Dec 2021)

BSE; Screener.in

Previous close before last trade

₹2.87

BSE

52-week high / low (as of last trade)

₹11.69 / ₹2.73

BSE

Market cap (full / free float)

₹4.08 Cr / ₹2.66 Cr

BSE

10-year price CAGR (to last trade)

-20%

Screener.in

5-year price CAGR (to last trade)

-1%

Screener.in

1-year and 3-year returns (to Oct 2026)

Not measurable; stock suspended since Dec 2021

—

Trading status

Suspended (BSE: non-payment of ALF dues); NSE series BZ

BSE; Screener.in

Valuation Snapshot by Multiple

MultipleValueBasis

EV (derived)

~768 (₹ Cr)

Market cap ₹4.08 Cr + borrowings ₹764 Cr (Sep 2020); cash not disclosed

EV/Sales (derived)

~128x

EV ~₹768 Cr / TTM revenue ₹6 Cr

Dividend metric

Dividend metricFY2009FY2010FY2011FY2012FY2013FY2014

Dividend payout ratio (%)

17163016130

Implied DPS derived as EPS times payout (INR)

1.962.071.992.001.550

Credit Ratings

AgencyRatingDateFacilities

CRISIL

D (Issuer Not Cooperating)

27 Nov 2025 (reaffirmed; same rating 30 May 2022, 28 Jul 2023, 30 Sep 2024)

Cash credit ₹3.50 Cr; term loan ₹7.18 Cr; proposed long-term facility ₹21.82 Cr; total ₹32.5 Cr

Moody's / S&P / Fitch

Not rated

——

Analyst Conclusions

Management guidance and consensus

Management guidance: none published. Consensus estimates: none (no coverage). The company has filed no financial results for more than six years' worth of quarters since Sep 2020.

Bull case (low probability)

  1. Asset backing for a court-supervised realisation. Fixed assets of ₹137 Cr and investments of ₹169 Cr (Sep 2020 book) could, if not confiscated, fund partial creditor and investor recovery under Calcutta HC supervision.

  2. Liability shrinkage via write-backs. Q2 FY2021's ₹124 Cr other income suggests liabilities can be extinguished; if related-party debts (dominant in the CoC) are disallowed or subordinated, the effective debt burden could fall sharply.

  3. Clean-slate restructuring. The recall of a fraudulent CIRP could open the door to a genuinely independent restructuring, preserving the listed shell's value for minority shareholders.

Bear case (high probability)

  1. Equity is deeply out of the money. Liabilities of ~₹806 Cr (₹764 Cr borrowings + ₹42 Cr other liabilities) against ₹422 Cr of book assets at Sep 2020, before any further impairment.

  2. PMLA primacy. The NCLT ruled that IBC cannot be used to legitimise proceeds of crime; assets traced to the CIS can be confiscated, leaving little for shareholders.

  3. Delisting and disclosure collapse. No filings since 2020, unpaid listing fees and a non-cooperating rating status point toward compulsory delisting.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Outcome of NCLT hearing scheduled 5 Oct 2026 in ATIL CIRPIndicates how group insolvencies will be handled after HC stay
Any appeal by Sai Tech Medicare or the RP against the 3 Feb 2026 recall at NCLATCould revive or permanently close the Alchemist Ltd CIRP
CBI, ED and SEBI status reports to Calcutta HCCould establish fraud findings, offshore fund flows, and the role of Technology Parks Ltd
Special PMLA Court progress on ED complaintsConfiscation risk for company assets
BSE/NSE action on compulsory delistingDetermines whether minority shareholders retain any listed exit
Any filing of financial results for FY2021–FY2026Would reveal post-2020 asset and liability position
CRISIL annual review (due ~Nov 2026)Confirms continued default status

Analyst verdict

Alchemist Limited should be understood not as an investable company but as a legal estate. Its operating history divides cleanly into two eras. From FY2009 to FY2014 it was a growing, dividend-paying, low-margin trading and agri-processing business, peaking at ₹827 Cr of revenue. From FY2015 onward it became a shell: revenue collapsed to ₹19 Cr within two years, ~₹475 Cr of receivables stopped turning, borrowings froze at ~₹750 Cr with interest barely recognised, and net worth slid from positive ₹25 Cr to roughly negative ₹383 Cr by September 2020. The pattern — debt-funded receivables that never convert to cash, investments impaired shortly after being made, and liabilities owed largely to parties that do not charge commercial interest — is consistent with the fund-diversion narrative that the Enforcement Directorate has alleged across the Alchemist Group.

The February 2026 NCLT recall is the single most important fact for any stakeholder. By holding that the insolvency was engineered through collusion and that a related-party-dominated creditor committee cannot be allowed to clean assets of criminal taint, the tribunal effectively ranked investor restitution and PMLA confiscation ahead of corporate resolution. The Calcutta High Court has reinforced that stance, freezing group CIRPs and directing agencies to trace offshore flows.

For minority shareholders, the economic conclusion is stark: liabilities materially exceed assets even at stale book values, assets face confiscation risk, the stock has not traded since December 2021, and the company has not filed results in six years. Equity value is best regarded as nil, with option value only in improbable scenarios. For creditors, recoveries depend on court-supervised realisation and on how related-party claims are treated. For researchers, the company is a case study in governance failure and the limits of the IBC. Verdict: uninvestable; monitor only for legal outcomes and delisting action.


Source list (primary references used)

  • Screener.in — Alchemist Ltd standalone and consolidated financials, shareholding, announcements (data from BSE filings): https://www.screener.in/company/ALCHEM/

  • BSE — RP intimation, 18 Apr 2022; trading-window letter, 4 Jan 2021; stock quote/suspension status (BSE code 526707)

  • IBBI — Public announcement and order register for CIN L72200DL1988PLC192643; lists of creditors (19 Jan 2022; 29 Jul 2022); Alchemist Holdings and Alchemist Capital CIRP records

  • CRISIL Ratings — Alchemist Limited rating rationale, 27 Nov 2025

  • Moneylife — NCLT recall of Alchemist Ltd CIRP (5 Feb 2026); ED attachment of hospital shares

  • LiveLaw — NCLT recall reasoning (12 Feb 2026); Calcutta HC order coverage (20 Apr 2026); KD Singh bail (Apr 2021)

  • Tax Concept — ED statement on NCLT recall (Feb 2026)

  • ATIL Resolution Professional — Calcutta HC intimation (2 Apr 2026); update on proceedings (1 Jul 2026)

  • IIFL — Alchemist Ltd company summary (history and name changes)

  • NSE — Press release on share consolidation, 27 Jul 2007

  • Business Standard; BFSL/Vogue Stock — ISIN, incorporation date, registered office, peer data

  • Yahoo Finance; MarketScreener; Financial Modeling Prep — management, employees, segments, products, plant locations

  • Wikipedia — K. D. Singh (politician); Anglia Ruskin University honorary award citation

  • The Wire; The Quint; Deccan Herald; Millennium Post; Daily Pioneer; Indian Express (via IIIT JPMC archive) — ED investigations, arrest, attachments

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / notesYear bornReported pay (₹, latest available year)Source

Bikram Bhattacharya

CEO & Whole-Time Director

Tenure start not disclosed

1953

2.78 million

Yahoo Finance

Anop Singh Negi

Chief Financial Officer

Since 10 Jul 2019

1973492,350

Yahoo Finance; MarketScreener

Divya Bajaj

Company Secretary & Compliance Officer

Resigned 6 Feb 2021

—348,000

Yahoo Finance; BSE

Gaurav Arora

VP, Marketing & Sales

—1978—

Yahoo Finance

Ajay Arora

VP, Steel & Floriculture

—1952—

Yahoo Finance

Madhu Tara

AGM, HR & Administration

—1975—

Yahoo Finance

Anjali Saxena

Head of HR

—1959—

Yahoo Finance

Dr Inderjit Singh Virdi

MD, Alchemist Hospitals Ltd (group)

———

Yahoo Finance

“—” = not publicly disclosed.

Board of Directors

PersonRoleNotesSource

Dr Kanwar Deep Singh (b. 21 Aug 1961)

Founder; Chairman until 2012; thereafter Chairman Emeritus of the group

Rajya Sabha MP 2010–2020 (TMC from 2014); arrested by ED 12 Jan 2021; bailed Apr 2021. Has denied involvement and stated he was not a director/shareholder of the investigated CIS companies.

Wikipedia; LiveLaw; Moneylife

Karan Deep Singh

Son of founder; chairs the Alchemist Group

Named in 2018 Kolkata Police case; beneficial owner of Sorus Agritech, whose ₹127.33 Cr hospital shareholdings were attached by ED

Wikipedia; Moneylife

Board & Management Changes

DateChangeContext

10 Jul 2019

Anop Singh Negi appointed CFO

Per MarketScreener

6 Feb 2021

CS Divya Bajaj resigns

Weeks after the founder's ED arrest

30 Nov 2021

Board suspended; IRP Chandra Prakash takes control

CIRP admission

10 Feb 2022

Gaurav Misra confirmed as RP

NCLT order

3 Feb 2026

RP appointment nullified

NCLT recall order

Shareholding Trend

Holder category (%)Mar 2017Mar 2018Mar 2019Mar 2020Sep 2020

Promoters (%)

34.9734.9434.9434.9434.94

FIIs (%)

17.199.753.500.000.00

DIIs (%)

3.792.482.492.481.51

Public (%)

44.0552.8259.0762.5763.54

Number of shareholders

8,3478,5918,7088,64010,223

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsRelative positioning of Alchemist

Steel wire and welded mesh

Tata Steel (wires business), Usha Martin, Bansal Wire Industries, Rajratan Global Wire, numerous unorganised Punjab/Ludhiana mesh makers

Marginal; single plant at Ropar, sub-scale

Poultry and processed chicken (historical)

Venky's (India), Godrej Agrovet (Real Good Chicken), Suguna Foods, Licious

Exited / dormant; Republic of Chicken no longer reported

Pharma formulations (iron, calcium, nutraceutical)

Mankind Pharma, Alkem Laboratories, Macleods, Abbott India, numerous PCD/franchise players

Negligible share; small branded-generic portfolio

Floriculture

Fragmented; listed historical peer Karuturi Global (itself collapsed); many unlisted growers in Bengaluru, Pune, Himachal

Negligible

Chemical and mineral trading

Highly fragmented trading houses

Exited (trading collapsed FY2015–FY2016)

Diversified classification peers (per exchange data)

3M India, Balmer Lawrie, DCM Shriram Consolidated

Not comparable in scale

Key Competitors

CompanyMarket cap (INR Cr, per BFSL peer table)Notes

Alchemist Ltd

4.08

Last traded Dec 2021; suspended

3M India

38,053

Diversified peer per exchange classification

DCM Shriram Consolidated

18,038

Diversified peer

Balmer Lawrie

2,873

Diversified peer

Recent Developments

The company itself has made no exchange disclosures in this period.

Discrepancy note: LiveLaw's 20 Apr 2026 report refers to the "NCLT Kolkata's recall order," whereas the IBBI register and Moneylife identify the recall order as passed by NCLT New Delhi Bench IV. The IBBI record is treated as authoritative.

Company Snapshot

$1.9M

Revenue

189

Employees

1988

Founded

New Delhi, India

Headquarters

SWOT Analysis

Strengths

  • Tangible fixed assets. Net fixed assets of ₹140 Cr (FY2020) and ₹137 Cr (Sep 2020) across plants at Solan, Ropar and Sirmour (Screener.in; MarketScreener).
  • Long listing history. Listed on NSE and BSE since the early-to-mid 1990s with ISIN INE964B01033 and ~10,223 shareholders (Sep 2020), giving a listed vehicle of potential (if contested) value.
  • Existing product brands. Named pharma brands (Anemi-XT, Valcal-M, IGTG Forte, Gasease) and a 100-grade wire-mesh range (MarketScreener; IIFL).
  • Removal of fraudulent CIRP. NCLT's 3 Feb 2026 recall voided RP actions, preventing a resolution that the tribunal found would have prejudiced investors and PMLA proceedings (IBBI; LiveLaw).
  • Historical operating capability. The company ran ₹386–827 Cr of annual revenue profitably from FY2009 to FY2014 with consistent dividends (Screener.in).

Weaknesses

  • Negative net worth. Equity of -₹196 Cr (FY2020) worsening to ~-₹383 Cr (Sep 2020); book value -₹283/share (Screener.in).
  • Unserviceable debt. Borrowings ₹764 Cr against TTM revenue of ₹6 Cr; financial creditor claims of ~₹919 Cr admitted in CIRP (IBBI 29 Jul 2022).
  • Persistent losses. Net losses every year FY2015–FY2020, totalling ₹262 Cr, plus ₹188 Cr in H1 FY2021 (Screener.in).
  • Receivables quality. Debtor days of 9,597 in FY2020; implied receivables of ~₹368 Cr against ₹14 Cr revenue, largely written down in Sep 2020 quarter (Screener.in, derived).
  • Disclosure failure. No financial results since Sep 2020; CRISIL classifies the issuer as non-cooperating (Nov 2025); BSE listing fees unpaid.
  • Staff attrition and unpaid dues. 60 employee claims of ₹3.70 Cr admitted, including the CFO and senior VPs (IBBI).

Opportunities

  • Asset-based investor restitution. The Calcutta HC's 24 Mar 2026 order directs RPs to hand over group assets, potentially enabling an orderly, court-supervised realisation.
  • Fresh, bona fide insolvency or restructuring. With the fraudulent CIRP recalled, a genuinely independent creditor process (or a court-appointed administrator) could still emerge.
  • Sale of plants and brands. Fixed assets of ~₹137 Cr and pharma brands could be monetised individually.
  • Recovery of investments. ₹169 Cr of investments might yield value if counterparties are solvent.
  • Write-back gains. Q2 FY2021 recorded ₹124 Cr other income, likely from liability write-backs; further write-backs could reduce stated liabilities.
  • Regulatory clarity. Multiple agencies (CBI, ED, SEBI) filing status reports may accelerate final determinations on which assets are proceeds of crime.

Threats

  • PMLA confiscation. ED has filed a prosecution complaint (Mar 2021) and two supplementary complaints (Jul 2024, Sep 2025); assets could be confiscated.
  • Criminal findings. HC noted a prima facie case of fraud and "institutional subversion" (Apr 2026).
  • Delisting. Trading suspended; non-payment of listing fees and non-filing could lead to compulsory delisting, wiping out minority shareholders' liquidity.
  • Contingent liabilities. ₹315 Cr of contingent liabilities flagged (Screener.in).
  • Group contagion. Alchemist Township, Alchemist Holdings and Alchemist Capital are all in CIRP (2019, 2025, 2025).
  • Equity subordination. With liabilities far exceeding assets, equity holders rank last in any realisation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (exact date not confirmed)ED provisionally attaches ₹127.33 Cr of shares in Alchemist Hospital and Ojas Hospital, Panchkula, held by Sorus Agritech (beneficially owned by Karan Deep Singh) MoneylifeExtends attachments to promoter-family healthcare assets
4 Jun 2025NCLT New Delhi admits CIRP against group company Alchemist Holdings Ltd (CP IB 494/ND/2024), petition by KDS Corporation Pvt Ltd IBBIGroup-wide insolvency contagion; petitioner name bears the founder's initials
7 & 13 Jun 2025Public announcements in Alchemist Holdings CIRP (IP: Manoj Kumar Jain) IBBIClaims process opens
1 Aug 2025NCLT Chandigarh admits CIRP against Alchemist Capital Ltd IBBIFurther group insolvency
Sep 2025ED files second supplementary prosecution complaint before PMLA court MoneylifeProsecution widens
17 Oct 2025Operational claim of ₹1.19 Cr lodged in Alchemist Holdings CIRP IBBI claims listCreditor activity continues
27 Oct 2025CRISIL writes to company seeking information; no responseContinued non-cooperation
27 Nov 2025CRISIL reaffirms "D (Issuer Not Cooperating)" on ₹32.5 Cr facilitiesConfirms default status
3 Feb 2026NCLT New Delhi Bench IV recalls Alchemist Ltd CIRP in IA 1997/2025, holding it vitiated by fraud, collusion and malice; lifts moratorium; nullifies RP actions; imposes ₹5 lakh costs on Sai Tech Medicare IBBI; Moneylife; LiveLawLandmark ruling that IBC cannot shield proceeds of crime; restores PMLA primacy over company assets
4–6 Feb 2026ED publicises the outcome; Economic Times and others report Moneylife; ET (via NSE archive)Public signal of ED's position
12 Feb 2026LiveLaw reports reasoning: CoC dominated by related accused entities; Section 32A immunity cannot extinguish criminal liabilityLegal precedent
23 Feb 2026Alchemist Holdings creditor list updated IBBIOngoing group CIRP
24 Mar 2026Calcutta HC (WPA 1389/2017) directs NCLT to stay all group CIRPs, including implementation of resolution plans, and directs RPs to hand over assets ATIL RP intimationFreezes group insolvency; prioritises investors
1 Apr 2026HC order uploaded ATIL RP intimation—
2 Apr 2026ATIL RP informs CoC of HC order ATIL RP intimation—
18 Apr 2026Affidavit filed before NCLT apprising it of HC order ATIL update—
20 Apr 2026LiveLaw reports HC noted prima facie fraud and "institutional subversion," sought CBI/ED/SEBI reports on offshore fund movement and round-tripping, and directed CBI to probe Technology Parks Ltd's roleEscalation of criminal scrutiny
10 Jun 2026NCLT New Delhi stays ATIL CIRP in deference to HC order ATIL updateGroup CIRPs halted
1 Jul 2026ATIL RP issues proceedings update ATIL update—
5 Oct 2026Scheduled NCLT hearing in ATIL CIRP (outcome not yet reported in sources reviewed) ATIL updateMonitorable
30 Nov 2021(Context) CIRP admitted against Alchemist Ltd IBBI—
13 Dec 2021(Context) Last trade at ₹3.01 BSE—
19 Jan 2022(Context) Creditor list: ₹914.92 Cr secured FC claims (98.91%) IBBI—
18 Apr 2022(Context) RP Gaurav Misra intimates BSE of appointment—
29 Jul 2022(Context) Creditor list: ₹919.49 Cr admitted unsecured FC claims (97.83%); 60 employee claims ₹3.70 Cr IBBI—
9 Sep 2022(Context) NCLT stay order in IA 4176/2022 IBBI—
19 Jul 2024(Context) ED supplementary prosecution complaint Moneylife—
30 Sep 2024(Context) CRISIL D (INC) reaffirmed—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from INR 190 Mn in FY2016 to INR 140 Mn in FY2020.
Alchemist Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2016FY2017FY2018FY2019FY2020
Revenue190240270270140

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.